Long-Term Effects of Enteroaggregative E. coli After Infection Clearance

Post-Infectious Irritable Bowel Syndrome (PI-IBS)

Approximately 10% of patients who experience infectious gastroenteritis, including EAEC infections, will develop PI-IBS within 12 months, with this risk increasing to 14.5% beyond one year, according to the American Gastroenterological Association 1, 2
Patients face a 4.2-fold increased risk of developing IBS compared to uninfected individuals within the first year, which decreases to 2.3-fold beyond 12 months, as reported by the American Gastroenterological Association 3, 2
The prevalence of PI-IBS among those with infectious enteritis ranges between 4-36% depending on pathogen type and geographic location, according to the American Gastroenterological Association 1, 2

EAEC has been linked to serious long-term sequelae including malnutrition with or without persistent diarrhea, as stated by the Infectious Diseases Society of America 4

EAEC infection causes long-lasting changes in gut microbiota composition, leading to dysbiosis and ongoing symptoms, according to the American Gastroenterological Association 5, 6
Post-infection changes include increased visceral sensitivity in both small and large intestine, involving alterations in dorsal root ganglia neuronal excitability, as reported by the American Gastroenterological Association 6, 2
Increased intraepithelial lymphocytes and mast cells persist after infection, with upregulation of mucosal pro-inflammatory cytokines continuing long-term, according to the American Gastroenterological Association 6

Enteric infections can trigger additional chronic conditions, including Guillain-Barré syndrome, reactive arthritis, and post-infectious functional dyspepsia (PI-FD), as stated by the Infectious Diseases Society of America 4, the American College of Travel Medicine 7, and the American Gastroenterological Association 1
Overlap between PI-IBS and PI-FD is common, occurring in up to 50% of cases, according to the American Gastroenterological Association 1, 2

The first step in management is educating patients about the link between intestinal infections and subsequent IBS development, as recommended by the American Gastroenterological Association 5, 6
Provide reassurance that symptoms are likely to improve or resolve over time in many patients, particularly with viral-associated PI-IBS, but acknowledge that a significant minority will have persistent symptoms requiring ongoing management, according to the American Gastroenterological Association 6, 1
There are no specific treatments for PI-IBS; management should follow general IBS treatment guidelines based on the predominant bowel habit subtype (IBS-D, IBS-M, or IBS-C), as stated by the American Gastroenterological Association 5, 6

Enteroaggregative E. coli causes persistent malnutrition after infection clearance through lasting intestinal mucosal damage, chronic inflammation, disruption of the gut microbiome, and impaired nutrient absorption—effects that are particularly severe in children and can lead to growth retardation even when diarrhea has resolved 8
The enterocyte damage impairs the absorption of macronutrients and micronutrients, leading to progressive malnutrition 8

Children face the most severe long-term consequences, with repeated early childhood EAEC infections causing cumulative effects on growth and cognitive development 8
The impact of repeated infections in early childhood can result in substantial long-term disability 8
HIV-infected adults are at particular risk for persistent diarrhea and more severe nutritional consequences 9

Enteral nutrition maintains gut mucosal integrity, decreases intestinal permeability, and improves immunological status 10, 11, 12
EN during episodes of diarrhea may improve enterocyte healing and maintenance of enzyme activity 11, 12
Avoid prolonged use of elemental diets, as they deprive the colonic microbiota of dietary fibers and resistant starch, potentially worsening dysbiosis 11, 12

The American Gastroenterological Association suggests that post-infectious irritable bowel syndrome with constipation (PI-IBS-C) affects 10-14.5% of patients after bacterial gastroenteritis, with a 2.3-fold increased risk beyond 12 months 13, 14
Bacterial gastroenteritis causes greater mucosal damage than viral infections, leading to higher PI-IBS rates, according to the American Gastroenterological Association 13, 14

The American Gastroenterological Association recommends stool testing, including C. difficile toxin PCR and bacterial culture/PCR panel, to exclude ongoing infection and structural disease 13, 14, 15
Inflammatory markers, such as complete blood count, C-reactive protein, and fecal calprotectin, should be assessed to evaluate ongoing inflammation, as suggested by the American Gastroenterological Association 13, 14

The American Gastroenterological Association recommends following general IBS treatment guidelines for PI-IBS, including osmotic laxatives, secretagogues, dietary modifications, and probiotics, although specific treatments for PI-IBS are not available 16, 15
Patient education should include reassurance that symptoms are likely to improve or resolve over time, although a significant minority may have persistent symptoms requiring ongoing management, according to the American Gastroenterological Association 13, 14